Thrombotic thrombocytopenic purpura during interferon alpha treatment for chronic myelogenous leukemia.
Thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome have recently been observed in patients undergoing interferon alpha (IFN-alpha) therapy. However, the relationship between disease and therapy has not been established, essentially because of concomitant treatment or previous bone marrow transplantation. We present a case of TTP developing during IFN-alpha therapy for chronic myelogenous leukemia. In this case, IFN-alpha seems to be the only etiological agent.
Lacotte
L
L
Department of Hematology and Clinical Oncology, CHU La Miletrie, Poitiers, France.
Thierry
A
A
Delwail
V
V
Dreyfus
B
B
Guilhot
F
F
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000150:complications / Q000188:drug therapy*; D008297:Male; D011697:Purpura, Thrombotic Thrombocytopenic / Q000139:chemically induced* / Q000150:complications
D000970:Antineoplastic Agents; D016898:Interferon-alpha